HAYWARD, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2010. Revenue for the third quarter was $24.9 million, an increase of approximately $7.1 million, or 40%, as compared to the third quarter 2009 revenue of $17.8 million. The improved results for the quarter were driven primarily by a year-over-year 40% increase in sales of treatment tips and consumables. Total revenue for the quarter from treatment tips and consumables of $13.4 million rose by $3.8 million as compared to $9.6 million for the third quarter of 2009.
Solta Medical's GAAP reported results for the third quarter of 2010 include non-cash amortization and other charges of $1.3 million related to the acquisitions of Reliant Technologies and Aesthera Corporation and non-cash stock based compensation charges of $0.6 million. The Company provides additional non-GAAP financial measures that exclude these charges and expenses.
The GAAP gross profit for the quarter was $15.7 million or 63% of net revenue. Non-GAAP gross profit for the quarter was $16.7 million or 67% of net revenue. GAAP net loss for the quarter was $1.4 million, or $0.02 per share as compared to GAAP net loss of $6.2 million, or $0.13 per share reported for the third quarter of 2009. Non-GAAP net income for the quarter was $0.5 million, or $0.01 per share on a diluted basis as compared to non-GAAP net loss of $4.2 million, or $0.09 per share reported for the third quarter of 2009. Non-GAAP EBITDA for the third quarter was $0.8 million compared to a loss of $3.8 million in the prior year period.
"We generated a year-over-year improvement in profitability for the quarter of nearly $5 million that was driven by increases in treatment tip revenue of over 30% in North America and nearly 50% in international markets. We also continue to focus on asset management. Inventory levels have declined from year-end 2009 by $2.7 million to $11.4 million at the end of Q3 and days sales outstanding on receivables remain below 40 days," said Stephen J. Fanning, Chairman, President & CEO. "In addition, with our acquisition last month of CLRS Technology we are excited to be providing consumers with an effective in-home acne solution, CLARO. The acquisition marks an expansion of our personal care initiatives. We continue to make progress in our project with Philips Consumer Lifestyle to develop and commercialize a home-use, laser-based device for skin rejuvenation. We have submitted a 510(k) application to the FDA for the device."
Financial Goals for 2010The company's financial goals for 2010 are as follows:
Non-GAAP PresentationTo supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses. The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.
Conference Call Information The Company will also host a conference call and webcast today, Tuesday, November 2, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 800-762-8795 for domestic participants and 480-629-9774 for international participants.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers. Callers will need to use the Passcode 4374781#. To access the live webcast of the call, go to Solta Medical's website at www.solta.com and click on Investor Relations. An archived webcast will also be available at www.solta.com.
About Solta Medical, Inc.Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the only FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our financial goals for 2010. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-Q for the quarter ended June 30, 2010, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Web Site: http://www.Solta.comSolta Medical, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of dollars, except share and per share data)(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009Net revenue
$24,851$17,753$80,866$70,415Cost of revenue
15,74110,44251,25640,820Operating expenses:Sales and marketing
10,1708,95831,48728,471Research and development
4,1354,23912,53012,104General and administrative
3,2903,79311,00211,563Legal settlement gain
——(2,213)—Total operating expenses
17,59516,99052,80652,138Loss from operations
(1,854)(6,548)(1,550)(11,318)Interest and other income
502195266432Interest and other expense
(62)(136)(243)(287)Gain on investments
—159—224Loss before income taxes
(1,414)(6,330)(1,527)(10,949)Provision (benefit) for income taxes
($1,406)($6,246)($1,830)($10,936)Net loss per share — basic
($0.02)($0.13)($0.03)($0.23)Net loss per share — diluted
($0.02)($0.13)($0.03)($0.23)Weighted average shares outstanding used in calculating net loss per share:Basic
59,519,11647,855,42858,663,81647,807,180Solta Medical, Inc.NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE (in thousands, except share and per share data)(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009GAAP Gross margin
$15,741$10,442$51,256$40,820Non-GAAP adjustments to gross margin:Amortization and other non-cash acquisition related charges
6661208175Non-GAAP gross margin
$16,747$11,398$54,406$45,914Non-GAAP gross margin as % of sales
67%64%67%65%GAAP loss from operations
($1,854)($6,548)($1,550)($11,318)Non-GAAP adjustments to net loss from operations:Amortization and other non-cash acquisition related charges
6038231,9232,476Non-GAAP income (loss) from operations
$802($3,846)$7,493($775)GAAP net loss($1,406)($6,246)($1,830)($10,936)Non-GAAP adjustments to net income (loss):Amortization and other non-cash acquisition related charges
6038231,9232,476Non-GAAP net income (loss)
$503($4,194)$5,068($2,438)GAAP basic net loss per share
($0.02)($0.13)($0.03)($0.23)Non-GAAP adjustments to basic loss per share:Amortization and other non-cash acquisition related charges
$0.01$0.02$0.03$0.06Non-GAAP basic net income (loss) per share
$0.01($0.09)$0.09($0.05)Non-GAAP diluted net income (loss) per share
$0.01($0.09)$0.08($0.05)GAAP weighted average shares outstanding used in calculating basic net loss per share
59,519,11647,855,42858,663,81647,807,180GAAP weighted average shares outstanding used in calculating diluted net loss per share
59,519,11647,855,42858,663,81647,807,180Adjustments for dilutive potential common stock
1,701,112-1,926,538-Weighted average shares outstanding used in calculating non-GAAP diluted net income (loss) per share
61,220,22847,855,42860,590,35447,807,180Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)September 30, December 31,20102009ASSETSCurrent assets:Cash and cash equivalents
11,43114,117Prepaid expenses and other current assets
4,4314,748Total current assets
61,55745,990Property and equipment, net
6,4215,613Purchased intangible assets, net
$153,810$136,149LIABILITIES AND STOCKHOLDERS’ EQUITYLiabilities:Accounts payable
10,00710,968Current portion of deferred revenue
438529Total current liabilities
29,04731,528Deferred revenue, net of current portion
686612Term loan, net of current portion
4891,626Non-current tax liabilities
32,37435,912Stockholders’ equity:Common stock, $0.001 par value: 100,000,000 shares authorized and 59,526,752 shares issued and outstanding at September 30, 2010 and December 31, 2009
6048Additional paid-in capital
(70,924)(69,094)Total stockholders’ equity
121,436100,237Total liabilities and stockholders’ equity
|SOURCE Solta Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved